Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

69.88 -0.21 (-0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Belite Bio, Inc - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Dow Tumbles Over 200 Points; Chicago PMI Drops In May
U.S. stocks traded lower this morning, with the Dow Jones dropping over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.68% to 32,817.80 while the NASDAQ fell... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Gainers VIQ Solutions Inc. (NASDAQ: VQS) shares rose 66.8% to $0.3887 in pre-market trading. 
Via Benzinga
HP, Ambarella, Sportsmans Warehouse And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
From Belite Bio, Inc
Via GlobeNewswire
3 Breakout Growth Stocks to Buy for the Long Haul
These three have had big-time share gains backed up by breakthrough science. 
Via The Motley Fool
2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023
Find out how these stock rockets could continue their ascent. 
Via The Motley Fool
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. 
Via Benzinga
Imago BioSciences, GrafTech International And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones dropping around 70 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
From Belite Bio, Inc
Via GlobeNewswire
3 Soaring Biotech Stocks That Could Climb Much Higher
These drugmakers have bucked the overall market's downward trend this year and expectations are still high. 
Via The Motley Fool
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued... 
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday's Mid-Day Session
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares jumped 64.5% to $2.03 after the company announced it has received its largest single purchase order for LinearDNA™ valued above the... 
Via Benzinga
Alphatec Holdings, Immatics And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Monday. Here are some big stocks recording gained in today’s session. 
Via Benzinga
Tesla, ABB And Other Big Losers From Monday
U.S. stocks closed sharply higher with the Dow Jones jumping more than 750 points on Monday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per... 
Via Benzinga
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month. 
Via MarketBeat
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today
Both companies presented data at the American Academy of Ophthalmology meeting. 
Via Investor's Business Daily
Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
From Belite Bio, Inc
Via GlobeNewswire
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback